SUVEN GETS DCGI NOD FOR PHASE I TRIALS OF SUVN-502

Search News

Pharmaceutical firm Suven Life Science has said that it has received permission from Drug Controller General of India to conduct Phase I clinical trials of SUVN-502, a product used in the treatment of Alzeimer disease. The drug is also used in the treatment of other disorders of memory like attention deficient hyperactivity, parkinson and schizophrenia, Suven said in a filing to the BSE. SUVN-502 is the lead compound, selected from a series of more than 500 compounds, which were designed and developed using the combination of traditional and rational medical chemistry approaches, the filing added.

Find Lawyer / Law Firm

Importance of Immigration Lawyers

As Indians we know India in itself is an amazing nation and even the world agrees with that, however, grass is always greener on the other side and that is why Indians desire to immigrate a More

Legal Consultation - Consult over phone, chat or send questions

Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion  More